News

Without GLP-1 Hims & Hers Is A $20s Per Share Stock -- Sell Call
Novo Nordisk ends partnership with Hims & Hers, causing a 35% plunge. With no near-term catalysts, learn why investors must ...
Hims & Hers Stock Tumbles as Novo Nordisk Ends Its Wegovy Sales Deal. Can the Telehealth Giant Recover?
The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.
Hims ‘Won’t Cave’ to Novo Demands Over Copycat Weight-Loss Shots, CEO Says
Hims & Hers Health Inc. won’t back down from selling cheap weight-loss shots, its chief executive officer said one day after ...
What's Going On With Hims & Hers Health Stock Today?
Hims & Hers Health Inc. (NYSE: HIMS) shares are trading higher Thursday. The stock appears to be bouncing back a bit after ...
Novo Nordisk halts Wegovy sales on Hims & Hers, claiming "deceptive marketing" practices
Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...
Medical Marketing & Media12h
Novo breaking up with Hims & Hers offers medical marketers a lesson
Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.
Novo Nordisk ends collaboration with Hims & Hers for discounted weight loss meds
Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for ...
Hims & Hers Sued Over Wegovy Maker’s Exit, Record Stock Selloff
Hims & Hers Health Inc. investors have sued the telehealth provider days after Novo Nordisk A/S announced it was ending the ...
HIMZ: Buy For Short-Term Gains On Hims & Hers Health, But Be Wary Of The Risks
Gain 2x leveraged exposure to HIMS with HIMZ, ideal for high-risk traders. Read more on how to navigate recent volatility and ...